Global Cancer Biomarker Market, by Biomarker Type (Genetic Biomarker, Protein Biomarker and Others),

Published Date: | Report Code : HC192599

X

Cancer Biomarker Market is projected to register high demand during the forecast period with increasing demand from major end-use industries such as hospitals, academic & cancer research institutes, ambulatory surgical centers, and cancer diagnostic laboratories during the forecast period. Governments are taking initiatives on the prevention and early intervention of cancer which is becoming a major issue in the current stage. To reduce the impact of cancer on patients and their families, various diagnosis and treatment process is getting advanced with innovative technologies. One of the major diagnosis processes includes cancer biomarkers considered to be routine diagnostic tests. The markers involved in molecular alterations with the application of DNA, microRNAs, proteins, and DNA. These alterations not only helps in the diagnosis of the current stage of cancer but also used for the early diagnosis of cancer. Increasing government investments in cancer research is one of the important drivers initiating the growth of the cancer biomarker market. For instance, in June 2018, Cancer Research UK has given a fund of USD140,922 per year for biomarker assay development, to be used in cancer clinical diagnosis.

However unfavorable reimbursement policies for cancer biomarkers is one of the key factors restraining the growth of the cancer biomarkers market. For instance, in 2014, according to the Cancer Action Network, in the US, cancer patients paid around USD 4 billion out-of-pocket expenses for cancer treatment. This unfavorable reimbursement policy making the treatment cost more expensive for the patients.

Some of the key Impact Factors:

  • Increasing government investments
  • Increasing cancer patients counts

Regional Outlook:

North America, Western Europe, and Asia Pacific by region are estimated to dominate the cancer biomarker market during the forecast period. These regions have been market leaders for the overall healthcare sector in terms of technological developments and advanced medical treatments. Moreover, the government policies have been favorable for the growth of the healthcare infrastructure in these regions. North America and Western Europe have an established healthcare infrastructure for product innovations and early adaptations. This is expected to drive the demand for cancer biomarker market during the forecast period. 

The US, Germany, France, UK, Canada, and Spain have been some the major markets in the region. Asia Pacific is estimated to register one of highest CAGR for cancer biomarker market during the forecast period. This region has witnessed strategic investments by global companies to cater the growing demand in the recent years. China, Japan, India, South Korea, and Australia are amongst some of the key countries for cancer biomarker market in the region. Other regions including Middle East, Eastern Europe, and Rest of the World (South America and Africa) are estimated to be emerging markets for cancer biomarker during the forecast period.

Companies Covered: BioMerieux.A., Bard Life Sciences Limited, Bio-Rad Laboratories, Abbott Laboratories, Becton, Dickinson and Company, Merck & Co., Inc., Qiagen N.V., Thermo Fisher Scientific Inc…..

Market Segmentation:

By Biomarker Type:

  • Genetic Biomarker
  • Protein Biomarker
  • Others

By Cancer Type:

  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Kidney Cancer
  • Liver Cancer
  • Others

By End User:

  • Hospitals
  • Academic & Cancer Research Institutes
  • Ambulatory Surgical Centers
  • Cancer Diagnostic Laboratories

By Region:

  • North America
    • By Country (US, Canada, Mexico)
    • By Biomarker Type
    • By Cancer Type
    • By End-User
  • Western Europe
    • By Country (Germany, UK, France, Italy, Spain, Rest of Western Europe)
    • By Biomarker Type
    • By Cancer Type
    • By End-User
  • Eastern Europe
    • By Country (Russia, Turkey, Rest of Eastern Europe)
    • By Biomarker Type
    • By Cancer Type
    • By End-User
  • Asia Pacific
    • By Country (China, Japan, India, South Korea, Australia, Rest of Asia Pacific)
    • By Biomarker Type
    • By Cancer Type
    • By End-User
  • Middle East
    • By Country (UAE, Saudi Arabia, Qatar, Iran, Rest of Middle East)
    • By Biomarker Type
    • By Cancer Type
    • By End-User
  • Rest of the World
    • By Region (South America, Africa)
    • By Biomarker Type
    • By Cancer Type
    • By End-User

Reasons to buy this report:

  • Market size estimation of cancer biomarker market on a regional and global basis
  • The unique research design for market size estimation and forecasts
  • Profiling of the major companies operating in the market with key developments
  • Broad scope to cover all the possible segments helping every stakeholder in the market

Customization:

We provide customization of the study to meet the specific requirements:

  • By segment
  • By sub-segment
  • By region/ country

For more information, contact: [email protected]

License Offering

Single User (PDF)

3850

Multi User (PDF)

5150

Enterprise User (PDF)

7650

 Regional Analysis

Your personal details are secure. Privacy Policy

Buy Chapters of Sections

Avail customized purchase options to meet your exact research needs.

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities
Detailed Coverage

Detailed scope covering all the major segments in the market

Meticulous Data Validations

In line data validations to ensure data precision

Recommendations

Market recommendations supporting decision making processes

Analyst Support

Round the clock analyst support to resolve your queries

Free Customization

Up to 15% additional free customization to meet your specific requirements

15% Free Customization

Share your Requirements

Questions?  Speak to an Analyst

Your personal details are secure. Privacy Policy